RenalGuard® Prevents Acute Kidney Injury (AKI) at Multiple Clinical Settings


RenalGuard automates precision fluid management, integrating seamlessly into existing clinical workflow.

The system responds to minute fluctuations in urine output, automatically adjusting IV fluid administration in milliliter increments, keeping patients hemodynamically stable and preventing over- or under-hydration.

Our goal: Eliminating Cardiac Surgery Associated-AKI (CSA-AKI)

A staggering 30% of patients suffer from AKI post-cardiac surgery.4 This results in extended hospital stays, higher mortality rates, and increased healthcare costs. Current protocols such as the KDIGO bundle are inadequate, and demonstrate almost no improvement in patient outcomes. 5
Kidney injury should not be collateral damage in cardiac surgery. Kidney injury should not be collateral damage in cardiac surgery. Kidney injury should not be collateral damage in cardiac surgery.
Kidney injury should not be collateral damage in cardiac surgery. Kidney injury should not be collateral damage in cardiac surgery. Kidney injury should not be collateral damage in cardiac surgery.

RenalGuard® for CSA-AKI protection demonstrates a 52% reduction in AKI 6

RenalGuard Therapy system balances IV fluid administration in response to the patient’s urine output in one ml increments which protects from AKI while preventing over- or under-hydration. In a 220-patient randomized control UK study, RenalGuard Therapy demonstrated a 52% reduction in AKI compared to standard care with no reported adverse events reported adverse events and post-surgery complications compare to standard of care.

Key Features

Dynamic

Adjusts IV fluid infusion in response to real-time urine output

Automated

Autonomous fluid balance management

Simple

Easy to set up and integrate into clinical practice

Validated

Validated technology in multiple studies and real-world settings

Approved

CE Approved for Fluid Management.

Many Settings

Core technology may be used for multiple clinical settings

The RenalGuard Console

The Console measures the volume of urine in the collection set and infuses an equal volume of hydration fluid, to match the patient’s urine output. It uses proprietary patented software and electronic weight measurements to control the fluid infusion rate and to monitor urine volume.

The Single Use Set

The proprietary disposable kits contain a urine collection set that connects to a patient’s Foley catheter and an infusion set that connects to a standard IV catheter.

Additional Clinical Applications

Contrast-Associated AKI (CA-AKI)

Contrast-Associated AKI (CA-AKI)

Contrast agents are commonly used in cath lab procedures, but can be toxic to the kidneys. Several independent investigator-initiated studies and EU clinical trials have demonstrated the efficacy and safety of RenalGuard Therapy in reducing this risk and preventing CA-AKI.

 

AKI in ICU Patients

AKI in ICU Patients

AKI affects over 50% of ICU patients, driven by sepsis, infections, and nephrotoxic medications. CRS has initial clinical results that demonstrate the potential for reduction of ICU related AKI based on the clinical principles of fluid management for prevention of CSA-AKI and CA-AKI.

1.      Brown JR, BioMed Research International. 2016:4278579.

2.      CDC Fast Stats: Death & Mortality.2019.

3.      CMS Announces Addition of Hospital Harm-AKI to Medicare’s Inpatient Quality Reporting (IQR) program

4.      Hu et al. Global Incidence & Outcomes of Adult Patients With AKI after Cardiac Surgery: A Systematic Review & Meta-Analysis. Cardiothorac Vasc Anesth. 2016;30:82-9 > 320,000 patients. Lau D, et al. Costs & consequences of AKI after cardiac surgery: A cohort study. J Thorac Cardiovasc Surg. 2021;162:880https://pubmed.ncbi.nlm.nih.gov/32299694/-887

5.      Current standard of care is based on the KDIGO guidelines, which suffer from poor compliance, due to complexity, and provide only minimal reduction in AKI. (PrevAKI Study). Potential Reno-protective Strategies in Cardiac Surgery. J Cardiothorac Vasc Anesth. (2021) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933995/.

6.      Heyman Luckraz et. al, Reduction in acute kidney injury post cardiac surgery using balanced forced diuresis: a randomized, controlled trial, European Journal of Cardio-Thoracic Surgery, Volume 59, Issue 3, March 2021. https://academic.oup.com/ejcts/article/59/3/562/6000632